The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development
AuthorAsiedu, Marina N.
Dib-Hajj, Sulayman D.
Waxman, Stephen G.
Price, Theodore J.
AffiliationUniv Arizona, Dept Pharmacol
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationThe AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development 2017, 12 (1):e0169882 PLOS ONE
Rights© 2017 Asiedu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractVoltage-gated sodium channels (VGSC) regulate neuronal excitability by governing action potential (AP) generation and propagation. Recent studies have revealed that AMP-activated protein kinase (AMPK) activators decrease sensory neuron excitability, potentially by preventing sodium (Na+) channel phosphorylation by kinases such as ERK or via modulation of translation regulation pathways. The direct positive allosteric modulator A769662 displays substantially greater efficacy than other AMPK activators in decreasing sensory neuron excitability suggesting additional mechanisms of action. Here, we show that A769662 acutely inhibits AP firing stimulated by ramp current injection in rat trigeminal ganglion (TG) neurons. PT1, a structurally dissimilar AMPK activator that reduces nerve growth factor (NGF) -induced hyperexcitability, has no influence on AP firing in TG neurons upon acute application. In voltage-clamp recordings, application of A769662 reduces VGSC current amplitudes. These findings, based on acute A769662 application, suggest a direct channel blocking effect. Indeed, A769662 dose-dependently blocks VGSC in rat TG neurons and in Na(v)1.7-transfected cells with an IC50 of similar to 10 mu M. A769662 neither displayed use-dependent inhibition nor interacted with the local anesthetic (LA) binding site. Popliteal fossa administration of A769662 decreased noxious thermal responses with a peak effect at 5 mins demonstrating an analgesic effect. These data indicate that in addition to AMPK activation, A769662 acts as a direct blocker/modulator of VGSCs, a potential mechanism enhancing the analgesic property of this compound.
NoteOpen Access Journal.
VersionFinal published version
SponsorsNIH [R01GM102575]; University of Texas; Medical Research Service and Rehabilitation Research Service, Dept. of Veterans Affairs
- Modulation of peripheral Na(+) channels and neuronal firing by n-butyl-p-aminobenzoate.
- Authors: Thériault O, Poulin H, Sculptoreanu A, de Groat WC, O'Leary ME, Chahine M
- Issue date: 2014 Mar 15
- Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin.
- Authors: Zhao F, Li X, Jin L, Zhang F, Inoue M, Yu B, Cao Z
- Issue date: 2016 Feb 16
- A769662 Inhibits Insulin-Stimulated Akt Activation in Human Macrovascular Endothelial Cells Independent of AMP-Activated Protein Kinase.
- Authors: Strembitska A, Mancini SJ, Gamwell JM, Palmer TM, Baillie GS, Salt IP
- Issue date: 2018 Dec 5
- No gain, no pain: NaV1.7 as an analgesic target.
- Authors: King GF, Vetter I
- Issue date: 2014 Sep 17
- Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs.
- Authors: Thériault O, Poulin H, Beaulieu JM, Chahine M
- Issue date: 2015 Oct 5